Law firms Pinsents and Linklaters act on latest big pharma deal as Teva sells Allergan generics business for £600m Legal Business · 6 October 2016 · 1 min read Corporate and M&A Deal watch Linklaters Pinsent Masons Pinsent Masons and Linklaters are advising on Teva Pharmaceutical Industries’ sale of UK and Ireland business Activas Generics for £603m as the Israeli firm seeks to divest assets following last year’s takeover of Allergan.Your limit of 1 article in 30 days is up. Please login for full access or subscribe. Corporate users - click here for simple access (no password needed). For more information, please contact [email protected] Related ContentMore in this categoryPinsents elects financial services head as new senior partnerLaw firmsWill Lewallen30 Jul 2026Linklaters and South African firm Webber Wentzel call time on 13-year allianceLaw firmsKate Peacock28 Jul 2026Linklaters posts double-digit PEP hike as turnover nears £2.5bnLaw firmsAlex Ryan21 Jul 2026US quartet lead on Grant Thornton’s landmark $5bn CBIZ acquisitionLaw firmsTheresa Hargreaves30 Jul 2026Freshfields and Slaughters set to share £40m-plus fees on EQT-Intertek dealLaw firmsTom Cox30 Jul 2026Macfarlanes closes in on £400m as PEP stays flatLaw firmsTom Cox29 Jul 2026Dealwatch: Global 100 advisers take centre stage on BlackRock-GIP $12.5bn mega dealLaw firmsAlex Ryan15 Jan 2024Dealwatch: Telegraph auction off as Barclay brothers pay off Lloyds debt with loanLaw firmsAlex Ryan8 Dec 2023Deal Watch: activity powers on as Latham and A&O lead on $19bn energy joint ventureLaw firmsMegan Mayers9 Sep 2022